Neurocrine Biosciences | NBIX - SCHULD





SCHULD Veränderung Datum
AbbVie USD 1000K 70.48B 2025-09
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 44.52M 4.24M 2025-09
ALKERMES USD 71.6M 1.08M 2025-09
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
Amgen USD 54.59B 1.62B 2025-09
Biogen USD 6.29B 1.7M 2025-12
BioMarin Pharmaceutical USD 604.24M 375K 2025-09
Cytokinetics USD 1.2B 338.79M 2025-09
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Exelixis USD 176.46M 3.38M 2025-09
Gilead Sciences USD 24.94B 5M 2025-09
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Incyte USD 40.41M 855K 2025-12
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Pfizer USD 60.85B 78M 2025-09
Prothena USD 9.08M 699K 2025-09
Regeneron Pharmaceuticals USD 2.71B 400K 2025-09
Repligen USD 542.21M 146.65M 2025-12
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Teva Pharmaceutical Industries USD 17.07B 450M 2025-09
Ultragenyx Pharmaceutical USD 33.83M 2.46M 2025-09
Vertex Pharmaceuticals USD 1.83B 307.4M 2025-09
Xoma USD 120.79M 3.27M 2024-06